Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): A randomised, double-blind, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 3, 2016, Pages 221-232

  Dejgaard, Thomas Fremming ^a,b   Frandsen, Christian Seerup ^b   Hansen, Tanja Stenbæk ^a   Almdal, Thomas ^b   Urhammer, Søren ^b   Pedersen Bjergaard, Ulrik ^b   Jensen, Tonny ^b   Jensen, Andreas Kryger ^b   Holst, Jens Juul ^b   Tarnow, Lise ^b,c   Knop, Filip Krag ^b   Madsbad, Sten ^b   Andersen, Henrik Ullits ^a  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; ALLERGIC REACTION; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPEPSIA; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART RATE; HERPES LABIALIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE ERYTHEMA; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; OBESITY; PNEUMONIA; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VITAMIN D DEFICIENCY; VOMITING; AGONISTS; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; OVERWEIGHT; TREATMENT OUTCOME;

EID: 84959481026     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00436-2     Document Type: Article

References (28)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
2. Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(suppl 1):S14-S80. American Diabetes Association.
3. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
4. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med 2010, 27:398-404.
5. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
6. Holst JJ Incretin hormones and the satiation signal. Int J Obes (Lond) 2013, 37:1161-1168.
7. Kielgast U, Holst JJ, Madsbad S Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011, 60:1599-1607.
8. Kjems LL, Holst JJ, Vølund A, Madsbad S The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
9. Eng C, Kramer CK, Zinman B, Retnakaran R Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014, 384:2228-2234.
10. Hari Kumar KV, Shaikh A, Prusty P Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 2013, 100:e55-e58.
11. Harrison LB, Mora PF, Clark GO, Lingvay I Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 2013, 61:40-44.
12. Kielgast U, Krarup T, Holst JJ, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34:1463-1468.
13. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013, 19:963-967.
14. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009, 32:2251-2257.
15. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014, 38:269-272.
16. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011, 165:77-84.
17. Kuhadiya N, Dhindsa S, Mehta A, et al. Liraglutide as additional treatment to insulin in patients with type 1 diabetes mellitus: a randomized clinical trial. 23rd Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE); Las Vegas; May 14-18, 2014. Abstract 295.
18. Dejgaard TF, Knop FK, Tarnow L, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open 2015, 5:e007791.
19. Hansen TK NBV: Type 1 diabetes mellitus (in Danish; accessed Sept 2, 2015). http://www.endocrinology.dk/index.php/1-diabetes-mellitus/3-type-1-diabetes-mellitus.
20. Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012, 303:E122-E131.
21. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320.
22. Sarkar G, Alattar M, Brown RJ, et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014, 37:666-670.
23. Hassan MK, Joshi AV, Madhavan SS, Amonkar MM Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003, 27:1227-1232.
24. Vitola BE, Deivanayagam S, Stein RI, et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity 2009, 17:1744-1748.
25. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998, 280:140-146.
26. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blinded parallel study. Diabetes Care 2015, published online Oct 20. 10.2337/dc15-1037.
27. Davies M, Speight J Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14:882-892.
28. Bradley C Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999, 22:530-532.